WillItSurvive
Pharma and healthcare groups · Japan

Santen Pharmaceutical

santen.com ↗

Japanese drugmaker, #1 in glaucoma treatments in Japan, sells eye drugs in 50+ countries.

Hard to displace
Assessed 26 July 2026 · Evidence as of 26 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 26 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: FY2026 Q1 earnings plus Japan approval decision on netarsudil (STN1013900) for glaucoma
The call

Santen still leads Japan's glaucoma market on trust and approvals, but flat revenue means new launches like Ryjunea and netarsudil have to work to keep it that way.

Santen makes medicines for eye diseases like glaucoma and has sold them in over 50 countries for decades. It is hard to knock off because each drug needs separate government approval and Japanese doctors trust Santen, but big companies like Alcon and Novartis already sell competing eye drugs worldwide and could take share if they tried harder. The company's real test is whether new medicines like Ryjunea for nearsightedness can replace sales from older drugs that lose patent protection, because flat or shrinking revenue would mean Santen is slowly fading rather than built to last.

Why
01
AI pressure: AI retinal screening tools like LumineticsCore (formerly IDx-DR). AI eye scanners already flag glaucoma and retinal disease earlier, which could reroute patients before they ever reach a Santen prescription. Could AI do the core job? Unlikely.
02
Bigger players: Alcon, AbbVie/Allergan, Novartis, Roche. These larger drugmakers already sell competing glaucoma and retinal treatments worldwide but have not taken Santen's Japan glaucoma lead. Could a giant copy it? Probably.
03
What protects it. Each glaucoma drug needs its own country by country regulatory approval, and Japanese doctors have trusted Santen's ophthalmology only sales network for decades.
What would change this call
Santen's revenue trend at and after the August 6, 2026 earnings release. Sustained decline despite new launches would show the core business is eroding faster than pipeline can offset.
Japan regulatory decision on netarsudil mesylate (STN1013900) glaucoma filing. Approval would refresh Santen's glaucoma cash cow; rejection or delay would widen the patent-cliff gap.
Ryjunea myopia sales uptake across EU markets following the Germany launch. Strong uptake shows Santen can offset domestic erosion with new geography; weak uptake shows pipeline is not replacing lost base.
Key numbers
  • FY2025 revenue ¥300.0 billion, essentially flat YoY (2025-12-24)
  • Net profit ¥36.3 billion, up 36.1% YoY (2025-05-13)
  • Over 70 products sold in 50+ countries (2024-07-05)
Named risks
  • Patent cliff on glaucoma cash-cow molecules with no confirmed approved replacement lined up. Severity: high
  • TTM revenue dipped to ¥287.99 billion by April 2026 versus ¥300.0 billion FY2025, showing possible erosion. Severity: medium
  • CJEU ruling on 'Santen doctrine' SPC interpretation could reshape IP protection scope for group. Severity: medium
  • AI-based retinal diagnostics could shift referral patterns away from traditional physician detailing. Severity: low
  • Key market-share claims (#1 Japan glaucoma) are self-reported without independent audit. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
AlconcontestingNamed as leading ophthalmology device/pharma peer, no Japan glaucoma share taken as of 2025-10-26
AbbVie/AllergancontestingListed among closest ophthalmic-pharma competitors, October 2025 industry report
RegeneroncontestingEYLEA co-marketed with Bayer in Japan alongside Santen's own retinal launches, May 2025
Bausch + LombcontestingActive rival in Fuchs Endothelial Corneal Dystrophy niche per October 1, 2025 report
NovartiscontestingCited as adjacent peer in ophthalmology drugs market report, October 26, 2025
Questions people ask
Is Santen Pharmaceutical profitable?
Yes. For the fiscal year ended March 31, 2025, Santen's net profit attributable to owners rose 36.1% year-on-year to ¥36.3 billion on revenue of ¥300.0 billion, a roughly 12.1% net margin, per its May 13, 2025 results disclosure.
Is Santen Pharmaceutical laying off employees?
No. Santen's headcount grew from 3,849 employees in March 2025 to 3,968 by March 2026 (+3.09% YoY per stockanalysis.com, June 2026), and it has not appeared in the 2025-2026 pharma layoff wave that hit Novo Nordisk, Bayer and Moderna.
Could AI replace Santen's drug business?
Unlikely. AI diagnostic tools like IDx-DR/LumineticsCore (FDA-cleared since 2018) help screen for eye disease but cannot obtain drug approvals or manufacture medicines; Santen still self-reports the #1 glaucoma market share in Japan as of May 2025.
Who is Santen Pharmaceutical's biggest competitor?
Industry reports (Towards Healthcare, October 26, 2025) name Alcon, AbbVie/Allergan, Novartis, Regeneron, Roche/Genentech and Bausch + Lomb as Santen's closest ophthalmology rivals, though none has displaced its Japan glaucoma leadership as of mid-2026.
Who owns Santen Pharmaceutical?
Santen is an independent public company listed on the Tokyo Stock Exchange Prime Market (ticker 4536), with ADRs trading as SNPHY; institutional holders control about 35% of shares as of April 6, 2026, per markets.ft.com.
Is Santen Pharmaceutical's revenue growing?
Growth is mixed: FY2025 (ended March 2025) revenue was ¥300.0 billion, essentially flat at -0.65% YoY, but trailing-twelve-month revenue had dipped to ¥287.99 billion by April 6, 2026, even as Q4 FY2025 alone grew 4.70% YoY.
Timeline
  • 2026-07-18Q4 FY2025 earnings report published; next call estimated for August 6, 2026
  • 2026-04-06Market cap reported at ¥588.31 billion; TTM revenue ¥287.99 billion
  • 2026-02-12CJEU referral reopens 'Santen doctrine' on SPC interpretation for veterinary medicines
  • 2025-09-01TAPCOM launched in China for glaucoma/ocular hypertension; share buyback announced
  • 2025-08-25SETANEO wins Japan manufacturing/marketing approval for glaucoma
  • 2025-08-19Licensing deal signed with RemeGen for retinal candidate RC28-E
  • 2025-07-30Applied for Japan approval of netarsudil mesylate (STN1013900) for glaucoma
  • 2025-07-22Ryjunea launched in Germany for pediatric myopia progression
  • 2025-06-05EU Commission approves Ryjunea for myopia progression
  • 2025-05-13FY2025 results disclosed: revenue ¥300.0 billion, net profit ¥36.3 billion (+36.1% YoY)
Revision history
26 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources